Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.44 |
| ▸ | CSF1R | P07333 | 9/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323125 | 0.88 | EGFR (0.44) | CSF1RLCKMAPK14EGFRGSK3B | |
| SCHEMBL15907191 | 0.81 | EGFR (0.43) | EGFRGSK3BGSK3AMEN1KMT2A | |
| SCHEMBL15907208 | 0.78 | BRAF (0.41) | KITDDR1CSF1RLCKMAPK14 | |
| SCHEMBL15907193 | 0.77 | ATR (0.36) | EGFRGSK3BGSK3AMAPTMEN1 | |
| SCHEMBL15907175 | 0.76 | PDE4A (0.39) | EGFRGSK3BGSK3A | |
| SCHEMBL15907281 | 0.74 | KIT (0.44) | KITDDR1CSF1R | |
| SCHEMBL15907180 | 0.70 | NPC1 (0.39) | EGFRGSK3BGSK3AMAPTMEN1 | |
| SCHEMBL29603322 | 0.69 | CA1 (0.49) | CSF1RMAPTMEN1KMT2A | |
| SCHEMBL30421445 | 0.69 | ATR (0.40) | MEN1KMT2A | |
| SCHEMBL11297044 | 0.69 | CA1 (0.49) | CSF1RMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KIT 577/4885DDR1 2472/4885CSF1R 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.